The ESQlabs Ecosystem for
Model-Informed Drug Development

With the latest release of MoBi®, featuring a powerful modularization capability, ESQlabs has built a robust modeling ecosystem designed to advance both Model-Informed Drug Development (MIDD) and Next-Generation Risk Assessment (NGRA) from end to end. The development behind MoBi®’s recent evolution was significantly supported by the OSMOSES project, a German grant project under our leadership.
We proudly present a transparent, flexible, and fully traceable ecosystem that meets the complex and evolving needs of modeling and simulation scientists in MIDD.
A Modular, Interoperable Framework for PBPK and QSP
Our ecosystem is an integrated, modular, and transparent framework that combines physiologically based pharmacokinetic (PBPK) and quantitative systems pharmacology/toxicology (QSP/QST) models into traceable and scalable end-to-end simulation workflows.
Built on open-source platforms like PK-Sim® and MoBi®, and fully compatible with R-based analytical pipelines, it empowers evidence-driven decision-making across all stages of drug development.
Advantages of Modularization in MIDD
Each model component can be developed, updated, and reused independently, and still integrates seamlessly with the overall model architecture:
This enables cross-team collaboration in a scalable manner, whether you’re conducting high-throughput PBPK screening or developing complex PBPK-QSP platforms for drug–drug interaction (DDI) assessments, special population modeling, exposure predictions, or therapeutic optimization.
The ecosystem supports full model lifecycle management, anchored in curated community libraries and collaborative databases:
- 01Model development
- 02Customization
- 03Qualification
- 04Quality assurance
- 05Regulatory reporting
Accelerate MIDD with a Transparent, Modular Modeling Ecosystem
Advance your model-based PBPK and QSP analyses with a seamlessly integrated modeling platform built for MIDD. Designed for qualified workflows for regulatory-level MIDD assessments, the ESQlabs ecosystem provides the tools and structure needed to perform transparent, auditable, and scalable assessments, anchored in validated models and collaborative libraries.
Why Choose the ESQlabs Ecosystem?
End-to-End Model Lifecycle Management
Efficiently develop, adapt, qualify, and reuse models through a modular, interoperable design, supported by a curated library of validated models and datasets to ensure robustness and regulatory compliance.
Seamless Integration with Analytical Tools
Connect modeling, simulation, and analysis tools effortlessly. Reduce manual handoffs and streamline workflows for faster, more reliable outcomes.
Flexible, Context-Specific Applications
Easily adapt models for diverse applications, including ADME-PK studies, DDI evaluations, special population simulations, and therapeutic optimization, without disrupting core architectures.
Transparency, Traceability, and Collaboration
Benefit from fully transparent, traceable workflows. Ecosystem model lifecycle management enables confident regulatory decision-making within cross-functional and cross-organizational collaboration, powered by community-driven libraries and standards.
Our MIDD services
PBPK for Drug–Drug Interactions Simulations
Find out more →Translational PBPK and First-in-Human Dose Predictions
Find out more →PBPK for Special Populations
Find out more →QSP for Disease, Drug Effect and Clinical Trial Simulations
Find out more →PBBM for Formulation Design, Selection and Quality Control
Find out more →PBPK and QSP for Veterinary Drug Development and Animal Safety
Find out more →Accelerate and de-risk your drug development projects with ESQlabs’ seamlessly integrated modeling ecosystem, where innovation meets traceability and modular design enables science at scale.